SMStanislav Motyka

Stanislav Motyka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stanislav Motyka has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deep Learning-Based Multiple Sclerosis Lesion Segmentation at 7 Tesla: Comparison of Single- and Multi-Contrast MRI Inputs

    by Anna Petrova, Ivan Petrovic, Marc Berger, Yanniklas Kravutske, Joel Leinkauf, Rebeka Rumbak, Lukas Haider, Eva Niess, Bernhard Strasser, Wolfgang Bogner, et al.

    Automated lesion segmentation can support rapid and reproducible quantitative assessment and long-term monitoring of multiple sclerosis. Ultra-high-field 7T MRI provides increased spatial resolution and lesion visibility but introduces challenges for automated analysis, including field inhomogeneity, susceptibility-related artifacts, and spatially varying image contrast. Although deep learning methods perform well at conventional field strengths, their application to 7T MRI remains underexplored. We evaluated nnUNet using FLAIR alone, MP2RAGE alone, and combined MP2RAGE+FLAIR. The dataset included 115 longitudinal 7T MRI scans from 57 patients with MS, with 20 scans from 11 independent patients reserved for testing. DeepMedic was included as a comparative architecture. On the test set, nnUNet achieved mean DSC values of 0.72, 0.71, and 0.66 for combined, MP2RAGE-only, and FLAIR-only inputs, respectively. No significant DSC differences were observed between nnUNet and DeepMedic. For both architectures, adding FLAIR to MP2RAGE did not show a statistically significant additional benefit in the present test cohort, whereas MP2RAGE-containing inputs significantly outperformed FLAIR-only input. The findings of the present study provide preliminary evidence suggesting that the observed voxel-level segmentation performance was primarily associated with the inclusion of MP2RAGE. However, lesion-level performance depended on lesion size, indicating further investigation of contrast-specific effects on small-lesion detection.

  • Open Access

    Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging

    by Alexandra Msc Lipka, Eva Niess, Assunta Dal-Bianco, Gilbert J. Hangel, Paulus S. Rommer, Bernhard Strasser, Stanislav Msc Motyka, Lukas Hingerl, Thomas Md Berger, Petra Hnilicová, et al.

    Background: Magnetic resonance spectroscopic imaging (MRSI) of the brain enables in vivo assessment of metabolic alterations in multiple sclerosis (MS). This provides complementary insights into lesion pathology that cannot be obtained via T1- and T2-weighted conventional magnetic resonance imaging (cMRI). Purpose: The aims of this study were to assess focal metabolic alterations inside and at the periphery of lesions that are visible or invisible on cMRI, and to correlate their metabolic changes with T1 hypointensity and the distance of lesions to cortical gray matter (GM). Methods: A 7 T MRSI was performed on 51 patients with relapsing-remitting MS (30 female/21 male; mean age, 35.4 ± 9.9 years). Mean metabolic ratios were calculated for segmented regions of interest (ROIs) of normal-appearing white matter, white matter lesions, and focal regions of increased mIns/tNAA invisible on cMRI. A subgroup analysis was performed after subdividing based on T1 relaxation and distance to cortical GM. Metabolite ratios were correlated with T1 and compared between different layers around cMRI-visible lesions. Results: Focal regions of, on average, 2.8-fold higher mIns/tNAA than surrounding normal-appearing white matter and with an appearance similar to that of MS lesions were found, which were not visible on cMRI (ie, ~4% of metabolic hotspots). T1 relaxation was positively correlated with mIns/tNAA (P ≤ 0.01), and negatively with tNAA/tCr (P ≤ 0.01) and tCho/tCr (P ≤ 0.01). mIns/tCr was increased outside lesions, whereas tNAA/tCr distributions resembled macroscopic tissue damage inside the lesions. mIns/tCr was −21% lower for lesions closer to cortical GM (P ≤ 0.05). Conclusions: 7 T MRSI allows in vivo visualization of focal MS pathology not visible on cMRI and the assessment of metabolite levels in the lesion center, in the active lesion periphery and in cortical lesions. This demonstrated the potential of MRSI to image mIns as an early biomarker in lesion development.


  • Open Access

    7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors

    by Gilbert Hangel, Philipp Lazen, Sukrit Sharma, Barbara Hristoska, Cornelius Cadrien, Julia Furtner, Ivo Rausch, Alexandra Lipka, Eva Niess, Lukas Hingerl, et al.

    (1) Background: Recent developments in 7T magnetic resonance spectroscopic imaging (MRSI) made the acquisition of high-resolution metabolic images in clinically feasible measurement times possible. The amino acids glutamine (Gln) and glycine (Gly) were identified as potential neuro-oncological markers of importance. For the first time, we compared 7T MRSI to amino acid PET in a cohort of glioma patients. (2) Methods: In 24 patients, we co-registered 7T MRSI and routine PET and compared hotspot volumes of interest (VOI). We evaluated dice similarity coefficients (DSC), volume, center of intensity distance (CoI), median and threshold values for VOIs of PET and ratios of total choline (tCho), Gln, Gly, myo-inositol (Ins) to total N-acetylaspartate (tNAA) or total creatine (tCr). (3) Results: We found that Gln and Gly ratios generally resulted in a higher correspondence to PET than tCho. Using cutoffs of 1.6-times median values of a control region, DSCs to PET were 0.53 ± 0.36 for tCho/tNAA, 0.66 ± 0.40 for Gln/tNAA, 0.57 ± 0.36 for Gly/tNAA, and 0.38 ± 0.31 for Ins/tNAA. (4) Conclusions: Our 7T MRSI data corresponded better to PET than previous studies at lower fields. Our results for Gln and Gly highlight the importance of future research (e.g., using Gln PET tracers) into the role of both amino acids.